Literature DB >> 10224221

Cyclin E in human cancers.

R Donnellan1, R Chetty.   

Abstract

Regulators of the cell cycle such as cyclin E play an important part in neoplasia. The cyclin E protein forms a partnership with a specific protein kinase. This complex phosphorylates key substrates to initiate DNA synthesis. Cyclin-dependent kinase inhibitors (CKIs) are able to suppress the activity of cyclin E. Various substances (including proteins produced by oncogenic viruses) affect cyclin E directly or indirectly through an interaction with CKIs. These interactions are important in elucidating the mechanisms of neoplasia. They may also provide prognostic information in a wide range of common cancers. Cyclin E may even be a target for treatment of cancers in the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224221     DOI: 10.1096/fasebj.13.8.773

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  62 in total

1.  Novel splice variants of cyclin E with altered substrate specificity.

Authors:  D C Porter; K Keyomarsi
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

2.  Dynamics of the cell cycle: checkpoints, sizers, and timers.

Authors:  Zhilin Qu; W Robb MacLellan; James N Weiss
Journal:  Biophys J       Date:  2003-12       Impact factor: 4.033

3.  The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles.

Authors:  Reiko Honda; Edward D Lowe; Elena Dubinina; Vicky Skamnaki; Atlanta Cook; Nick R Brown; Louise N Johnson
Journal:  EMBO J       Date:  2005-01-20       Impact factor: 11.598

Review 4.  Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.

Authors:  Mu-Shui Dai; Yetao Jin; Jayme R Gallegos; Hua Lu
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

5.  Constitutive turnover of cyclin E by Cul3 maintains quiescence.

Authors:  Justina D McEvoy; Uta Kossatz; Nisar Malek; Jeffrey D Singer
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

6.  Gastrokine-2 is downregulated in gastric cancer and its restoration suppresses gastric tumorigenesis and cancer metastasis.

Authors:  Jin Dai; Ning Zhang; Jinhui Wang; Minhu Chen; Jie Chen
Journal:  Tumour Biol       Date:  2014-01-10

7.  c-ETS1 facilitates G1/S-phase transition by up-regulating cyclin E and CDK2 genes and cooperates with hepatitis B virus X protein for their deregulation.

Authors:  Anup Kumar Singh; Manickavinayaham Swarnalatha; Vijay Kumar
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 8.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

9.  Expression of cyclin E in stage III colorectal carcinoma.

Authors:  Lea Rath-Wolfson; Michael Bergman; Yaacov Ori; Alex Goldman; Edward Ram; Rumelia Koren; Hertzel Salman
Journal:  Oncol Lett       Date:  2012-10-05       Impact factor: 2.967

10.  PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Authors:  Evan Gomes Giacoia; Makito Miyake; Adrienne Lawton; Steve Goodison; Charles J Rosser
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.